Teijin, Sigma-Tau ink orphan drug agreement in Japan
By Cornelia Zou
Thursday, June 26, 2014
Japan´s Teijin Pharma Ltd. entered an exclusive development and sales agreement with Sigma-Tau Pharmaceuticals Inc. that will allow Teijin to participate in the development of EZN-2279, a therapeutic agent for adenosine deaminase (ADA) deficiency, as well as to distribute the final product in Japan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.